Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Clara Moriana Domínguez"'
Autor:
Francisco José Borrego Utiel, María Victoria Camacho Reina, Clara Moriana Domínguez, Enoc Merino García
Publikováno v:
Nefrología, Vol 40, Iss 2, Pp 202-204 (2020)
Externí odkaz:
https://doaj.org/article/0896d4529ecb464783189a2e95de4fcf
Autor:
Francisco José Borrego Utiel, María Victoria Camacho Reina, Clara Moriana Domínguez, Enoc Merino García
Publikováno v:
Nefrología (English Edition), Vol 40, Iss 2, Pp 202-204 (2020)
Externí odkaz:
https://doaj.org/article/318765ed37fe4161b715d238bb8ed56f
Autor:
Maria Victoria Camacho Reina, Francisco José Borrego Utiel, Enoc Merino García, Clara Moriana Domínguez
Publikováno v:
Nefrología, Vol 40, Iss 2, Pp 202-204 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e54b2fc3c9913c682cf3ae307b31427c
http://www.sciencedirect.com/science/article/pii/S0211699519300888
http://www.sciencedirect.com/science/article/pii/S0211699519300888
Autor:
Enoc Merino García, Clara Moriana Domínguez, Francisco José Borrego Utiel, Rafael José Esteban de la Rosa, Juan Antonio Bravo Soto, Antonio Medina Benítez, Ana Isabel Morales García, Aurora Polo Moyano
Publikováno v:
American journal of nephrology. 52(8)
Introduction: Mayo clinic classification (MCC) has been proposed in patients with autosomal dominant polycystic kidney disease (ADPKD) to identify who may experience a rapid decline of renal function. Our aim was to validate this predictive model in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dd36f44b2c387ff0def1d38e1dae485
https://pubmed.ncbi.nlm.nih.gov/34518464
https://pubmed.ncbi.nlm.nih.gov/34518464
Autor:
Enoc Merino García, Francisco-Jose Borrego-Utiel, Maria Luisa Garnica Alvarez, Clara Moriana Domínguez
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Tolvaptan was approved to treat autosomal dominant polycystic kidney disease (ADPKD) to slow the rate of kidney growth and renal function decline. Tolvaptan blocks the V2 vasopressin receptor in renal collecting ducts and distal n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aef517d5a93015c00d9c9783794af4a
https://doi.org/10.1093/ndt/gfab092.008
https://doi.org/10.1093/ndt/gfab092.008
Autor:
Juan Antonio Bravo Soto, Enoc Merino García, Clara Moriana Domínguez, Aurora Polo Moyano, Francisco-Jose Borrego-Utiel, Rafael José Esteban de la Rosa, Ana Isabel Morales García
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims The Mayo Clinic classification (MCC) is used in patients with ADPKD to identify those who may experience a more rapid deterioration of glomerular filtration rate (GFR). It has been developed in the American population but has not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea8c8186b63477dc254406f02655cd5f
https://doi.org/10.1093/ndt/gfab090.0011
https://doi.org/10.1093/ndt/gfab090.0011
Autor:
Francisco José Borrego Utiel, Esther Ocaña Pérez, Maria Victoria Camacho Reina, Isidoro Herrera Contreras, Enoc Merino García, Clara Moriana Domínguez
Publikováno v:
International urology and nephrology. 54(4)
INTRODUCTION Autosomal dominant polycystic kidney disease (ADPKD) is frequent to find low urinary citrate levels. Recently, it has been suggested that urinary citrate could be a marker of covert metabolic acidosis in chronic kidney disease. OBJECTIVE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd6b2b87dd8f8ff44cf2dca4fde23b69
https://pubmed.ncbi.nlm.nih.gov/34279821
https://pubmed.ncbi.nlm.nih.gov/34279821
Autor:
Clara Moriana Domínguez, Francisco José Borrego Utiel, Enoc Merino García, María José García Cortés, Isidoro Herrera Contreras, Esther Ocaña Pérez
Publikováno v:
International urology and nephrology. 54(6)
In autosomal dominant polycystic kidney disease (ADPKD) it is frequently found a reduction in urinary citrate of unknown origin. It has been suggested that it could be a marker of acid retention in chronic kidney disease. Our aim was to compare urina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37af822370db19f59ccb908b92fe887a
https://pubmed.ncbi.nlm.nih.gov/34546556
https://pubmed.ncbi.nlm.nih.gov/34546556
Autor:
Clara Moriana Domínguez, Isidoro Herrera, Enoc Merino Garcia, Francisco-Jose Borrego-Utiel, Esther Ocaña Perez, Victoria Camacho Reina
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims In autosomal dominant polycystic kidney disease (ADPKD) is frequent to find low urinary citrate levels. Recently it has been suggested that urinary citrate could be a marker of covert metabolic acidosis. Our aim was to analyze rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80dcb8b63d2660ebcea107c415c427e9
https://doi.org/10.1093/ndt/gfaa142.p0035
https://doi.org/10.1093/ndt/gfaa142.p0035
Autor:
Isidoro Herrera, Esther Ocaña Perez, Francisco-Jose Borrego-Utiel, Victoria Camacho Reina, Maria Jose Garcia Cortes, Clara Moriana Domínguez, Enoc Merino García
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims In polycystic kidney disease (PKD) it is frequently found a reduction in urinary citrate that is related with degree of renal impairment but it is unknown if this alteration is specific or if it is also present in other nephropath
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0d5b21de77d4ddcb4648d77f4776633
https://doi.org/10.1093/ndt/gfaa142.p0234
https://doi.org/10.1093/ndt/gfaa142.p0234